Magenta Therapeutics CEO and leadership

Technology and Payments EntrepreneurSpecialties: Electronic payments, prepaid, merchant processing both on and offline, global remittance processing, financial services technologies, rent and lease related payments processing, payments compliance, money transfer, mobile money transfer.

As Chief Financial and Operating Officer, Mr. Mahoney will serve as a member of the Company’s Executive Team and will oversee all aspects of financial planning and analysis, as well as investor community engagement, including investor relations and other external stakeholder communications, in addition to R&D capital allocation strategy and operations and facilities management.

Mr. Mahoney comes to Magenta with more than 20 years of global biotechnology sector industry experience. Most recently, Mr. Mahoney served as President and Chief Operating Officer of Kiniksa Pharmaceuticals, Ltd., where the company raised capital in three private financing rounds, an initial public offering and a follow-on financing. Prior to his time at Kiniksa, Mr. Mahoney served as Chief Commercial Officer, among other executive titles of increasing responsibilities, at Synageva Biopharma. Previous to that, he was Regional Director, Legal - Asia Pacific Region for Genzyme Corporation, following other roles for the organization.

Mr. Mahoney holds a JD/MBA from Boston College and a BA from Colorado College.

As Chief Legal Officer, Mr. Beetham serves as a member of the Company’s Executive Team and is responsible for leading all aspect of Magenta’s legal and compliance operations.

Mr. Beetham has more than 20 years of experience in legal, business development, operations and strategy across the biotechnology and pharmaceutical industries. He joined Magenta most recently from Kiniksa Pharmaceuticals, where he served as Chief Legal Officer and Executive Vice President, Corporate Development and Operations, where he oversaw all company legal matters, including transactions, financings, corporate and securities, public company reporting, tax, international, real estate, human resources and more. Previously, he was Chief Legal Officer at Synageva BioPharma, among other roles of increasing responsibility. Mr. Beetham’s additional experience includes legal leadership roles at New England BioLabs, Inc; Genzyme Corporation; and Palmer & Dodge LLP.

Mr. Beetham holds JD and MBA degrees from Boston College and a Bachelor of Arts degree from the University of Rochester.

Head of Process Development and GMP Clinical and Commercial Manufacturing for Biologics and Small Molecules, Analytical Development and Quality Control, Cold Chain Logistics and Management.

Kristen Stants is Chief People Officer, responsible for leading the development, implementation and alignment of Magenta’s overall people strategy,

Kristen joins Magenta from Alexion Pharmaceuticals, where she served as Head of Talent Strategy, responsible for organizational development and talent acquisition to expand the company’s therapeutic pipeline. Prior to that, she led talent management and development strategy at Patheon Pharmaceuticals, in addition to 10 years at Biogen, where she held various leadership roles in executive development and organizational effectiveness. Her early career began in management consulting at Hewitt Associates, where she led research for Fortune Magazine’s 100 Best Companies to Work For.

She holds a Master of Industrial and Labor Relations with a concentration in Organizational Behavior from Cornell University and a Bachelor of Science in Psychology and Business from the University of Oregon.

Lisa Olson is Magenta’s Chief Scientific Officer and Head of Research; as such, Dr. Olson provides strategic direction, oversight and execution for Magenta’s research and discovery efforts. This entails driving research strategy as Magenta continues to optimize its preclinical and clinical pipeline. She is a member of Magenta’s executive team and the R&D leadership team.

Dr. Olson is an experienced senior-level pharmaceutical executive, with more than 20 years of experience in research and drug discovery. She came to Magenta following 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions, including new target approval, project advancement and licensing opportunities. Under her leadership, 15 molecules advanced into clinical development, including Upadacitinib that launched last year as Rinvoq™. Prior to AbbVie, she served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer, Inc. She began her career as an Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago.

Dr. Olson holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.

Technology and Payments EntrepreneurSpecialties: Electronic payments, prepaid, merchant processing both on and offline, global remittance processing, financial services technologies, rent and lease related payments processing, payments compliance, money transfer, mobile money transfer.

Technology and Payments EntrepreneurSpecialties: Electronic payments, prepaid, merchant processing both on and offline, global remittance processing, financial services technologies, rent and lease related payments processing, payments compliance, money transfer, mobile money transfer.